The docuseries presents compelling narratives at the intersection of science, innovation, and patient care, spotlighting healthcare institutions and caregivers contributing to transformative change in the medical field. As part of a four-episode Season 2 lineup, the feature on Fortis Cancer Institute highlights its integrated OncoSciences ecosystem, clinical excellence, and structured patient pathways that are redefining oncology care delivery in India, with growing international visibility.
The episode captures the journeys of two cancer patients, including one treated for Breast Cancer (stage 4) and another diagnosed with Blood Cancer (Leukemia). It documents how both patients, in collaboration with the expert medical team at Fortis Cancer Institute, Fortis Hospital Mulund, navigated complex treatment journeys with resilience, ultimately emerging cancer-free and returning to their families with renewed health and hope.
The clinical team featured in the episode includes Dr Avanish Saklani, Director – Surgical Oncology; Dr Boman Dhabar, Director – Medical Oncology; Dr Subhaprakash Sanyal, Director – Haemato-Oncology & BMT; Dr Arun Behl, Senior Consultant – Surgical Oncology; Dr Rupal Chheda, Consultant – Radiation Oncology; and Dr Amol Akhade, Senior Consultant – Medical Oncology.
Additional key contributors from the institute include Dr Pankaj Maheshwari, Senior Consultant – Urology; Dr Saurabh Patil, Senior Consultant – Urology; Dr Raj Kapadia, Consultant – Surgical Oncology; Dr Vivekanand Sharma, Consultant – Surgical Oncology; Dr Rathan Shetty, Consultant – Surgical Oncology; Dr Deepanjali Adulkar, Consultant – Radiation Oncology; and Dr Pushkar Ingle, Consultant – Radiation Oncology, all of whom play a crucial role in advancing cancer treatment at the Fortis Cancer Institute.
At the screening of Molecules of Hope Season 2 held at the hospital, the team present included (R-L) Fortis Hospital Mulund’s Dr Moule, Dr Beri, Dr Saklani, Dr Akhade, Dr Dhabar, Dr S. Narayani, Dr Sharma, and Ms Mavani.
Speaking on the feature, Dr Vishal Beri, Facility Director, Fortis Hospital Mulund, Mumbai, said, “Being featured on Molecules of Hope is a significant milestone for us. It showcases how innovation, clinical expertise, and compassionate care come together to transform cancer outcomes. At Fortis Mulund, we are committed to not just treating cancer but changing the way it is perceived by encouraging early detection, reducing stigma, and making advanced care more accessible - because today, hope really has a new story to tell.”
The feature arrives at a crucial time in April, when awareness days such as head & neck cancer, esophageal cancer, and testicular cancer are observed, reinforcing the importance of early detection and timely intervention. Fortis Hospital Mulund’s Fortis Cancer Institute aims to use this platform to strengthen engagement with communities, healthcare professionals, and stakeholders through awareness initiatives and proactive cancer care outreach.
Dr S Narayani, Business Head – Fortis Hospitals, Maharashtra, stated, “The future of cancer care in India will be defined by how effectively we integrate innovation with accessibility. Platforms like ‘Molecules of Hope’ help bring this narrative to the forefront. At Fortis, we see ourselves contributing to this next phase by building comprehensive oncology models that prioritise early detection, precision-led treatment, and continuity of care. Our endeavour is to not only deliver clinical outcomes, but to help shape a more progressive and patient-centric cancer care ecosystem in the country. From Mumbai, we are proud to contribute to a larger narrative on how cancer care in India is evolving and how institutions like ours can help shape wider conversations around the future of OncoSciences.”
As part of this initiative, Fortis will implement a series of engagement-driven activities, including community awareness programs, community screening initiatives that have already reached 1 lakh households, collaborations with general practitioners, and knowledge-sharing platforms aimed at extending the impact of the feature beyond the screen.
About IHH Healthcare, a leading multinational healthcare provider shaping the future of care under its aspiration to Care. For Good., it unites medical excellence and innovation through trusted brands such as Acibadem, Gleneagles, Fortis, Island, Mount Elizabeth, Pantai, Parkway, and Prince Court. Across 10 countries including Malaysia, Singapore, Türkiye, India, and Greater China, its 70,000-strong workforce delivers world-class care across more than 140 healthcare facilities, including over 80 hospitals. Its services span the full healthcare continuum from primary and ambulatory to quaternary care, along with diagnostics, imaging, rehabilitation, telehealth, and home care. In partnership with stakeholders, IHH advances value-based care, builds a sustainable healthcare ecosystem, and works toward becoming the world’s most trusted healthcare services network.
About The Author
Comment List